The timeline of carrier injection following tumor implantation is shown in Figure 2A. Carriers capable of expressing both p53 and Azurin were injected intracranially at the tumor implant site to a depth of 1.5 mm using a stereotax on days 7 and 14 post-tumor implant. The gene discussed is TP53; the disease is neoplasm.